New And Selective Radiolabelled alphaVbeta3 Peptide Antagonista As Tracer In Tumor Diagnosis

 

TITLE

New And Selective Radiolabelled alphaVbeta3 Peptide Antagonista As Tracer In Tumor Diagnosis

STAFF

Michele Saviano

KEYWORDS

Integrin, cancer, Drug Design, Selectivity

COLLABORATIONS


Istituto di Biostrutture e Bioimmagini-CNR Napoli

DESCRIPTION

Angiogenesis, the process whereby new capillaries are formed by outgrowth from existing microvessels, is required for tumor growth and metastasis. The transmembrane cell-surface receptor αVβ3 has recently received increasingly attention, because of the critical role in tumor associated angiogenesis and metastasis formation . The restricted expression of integrin αVβ3 during tumor growth, invasion, and metastasis presents an interesting target for both detection and treatment of solid tumors. Targeting αVβ3 with radiolabelled ligands may provide information about the receptor status and enable the planning and the monitoring of therapeutic approaches. Recently we developed a novel αVβ3 antagonist that showed a high selectivity for the receptor. Adhesion assays, competitive binding assays and cross-linking experiments performed in human erythroleukemia K562 cells, stably cotransfected with cDNA of αv or αIIb and β3, demonstrated the high selectivity for αVβ3 integrin. Starting from these evidences, RGDechi was covalently bound to the chelating agent DTPA able to give stable complexes of radionuclides, such as 111In and 90Y . The final goal has been to obtain a radiolabelled compound to be used in nuclear medicine as a diagnostic and therapeutic agent. In particular DTPA-RGDechi has been labeled with 111In and used in SPECT for diagnostic purpose. Moreover, the ligand RGDechi has been labeled with 18F for micro-PET in order to evaluate the use of this peptide for in vivo imaging.

 



References :

A. Del Gatto et al. Journal of Medicinal Chemistry (2006), 49(11), 3416-3420.
A. Del Gatto, et al. PCT Int. Appl. (2007)
C. Pedone, et al Radionuclide Peptide Cancer Therapy (2006), 1-30
A Zannetti et al Clin Cancer Res. (2009), 15(16), 5224-33

 

CONTACTS


Michele Saviano
Tel. +39 080 5929148
Fax +39 080 5929147
E-mail : michele.savianoATic.cnr.it

Last Updated (Tuesday, 21 December 2010 15:58)